Target intelligence / Profile preview

Distal-less homeobox 6 (DLX6)

Target
DLX6
Molecular classification
Transcription factor, Homeobox gene family, Developmental protein
01

Overview

Distal-less homeobox 6 (DLX6) is a member of the homeobox transcription factor gene family, highly conserved and similar to the Drosophila distal-less gene. The family comprises at least six genes instrumental in the development of the forebrain, craniofacial structures, limbs, and skeletal formation. In humans, DLX6 regulates enhancer elements responsible for gene expression in neural crest and forebrain derivatives, often working with its paralog DLX5. DLX6 activity is essential for the migration and differentiation of cortical interneurons, craniofacial identity (especially lower jaw patterning), limb development, and osteoblast differentiation for bone formation. Dysregulation, including abnormal antisense RNA (DLX6-AS1), is implicated in a variety of diseases such as neurodevelopmental disorders (often co-acting with DLX5), congenital craniofacial and limb malformations, and cancers. DLX6 is typically not a direct druggable target, but alterations in its gene network may inform disease mechanisms and biomarker development.

Other names
Homeobox protein DLX-6DLX6distal-less homeobox 6homeobox protein DLX-6
02

Mechanism of action

None reported (transcription factors like DLX6 are not classical drug targets; mechanisms involving DLX6/AS1 in disease focus on gene expression regulation, not direct pharmacologic mechanisms)

03

Biological functions

Regulation of forebrain and craniofacial developmentMigration and differentiation of cortical interneuronsCraniofacial morphogenesisLimb patterningOsteoblast differentiation and skeletal formation
04

Disease associations

Neurodevelopmental disorders (e.g., involvement in Rett syndrome)Craniofacial and limb malformations (e.g., split-hand/split-foot malformation)Cancer (notably, its antisense transcript DLX6-AS1 is implicated in non-small cell lung cancer and diabetic nephropathy)
05

Safety considerations

Not applicable; DLX6 is not a direct drug targetTherapeutic modulation (via gene therapy or RNA-based drugs) might risk developmental and skeletal abnormalities, given its critical developmental roles
06

Biomarkers

DLX6-AS1 (antisense transcript) may serve as a biomarker in cancers and kidney disease (diabetic nephropathy)

Beyond the preview

Go deeper on Distal-less homeobox 6 (DLX6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Distal-less homeobox 6 (DLX6).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call